Ionis-2026_01_14_JPMorgan_Presentation.pdf

1、44thAnnual J.P.Morgan Healthcare Conference 2026Brett Monia,Ph.D.Chief Executive OfficerBreakthrough Therapies Driving Accelerating GrowthJanuary 2026|Nasdaq:IONSForward-Looking StatementsThis presentation includes forward-looking statements regarding our business,financial guidance and the therapeu

2、tic and commercial potential of our commercial medicines,additional medicines in development and technologies and our expectations regarding development and regulatory milestones.Any statement describing Ionis goals,expectations,financial or other projections or guidance,intentions or beliefs is a f

3、orward-looking statement and should be considered an at-risk statement.Such statements are subject to certain risks and uncertainties including but not limited to those related to our commercial products and the medicines in our pipeline,and particularly those inherent in the process of discovering,

4、developing and commercializing medicines that are safe and effective for use as human therapeutics,and in the endeavor of building a business around such medicines.Ionis forward-looking statements also involve assumptions that,if they never materialize or prove correct,could cause its results to dif

5、fer materially from those expressed or implied by such forward-looking statements.Although Ionis forward-looking statements reflect the good faith judgment of its management,these statements are based only on facts and factors currently known by Ionis.Except as required by law,we undertake no obliga

6、tion to update any forward-looking statements for any reason.As a result,you are cautioned not to rely on these forward-looking statements.These and other risks concerning Ionis programsare described in additional detail in Ionis annual report on our Form 10-K for the year ended December 31,2024,and